Mediwound Ltd (NASDAQ:MDWD) was the target of a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 173,100 shares, a drop of 5.2% from the May 30th total of 182,600 shares. Based on an average trading volume of 81,700 shares, the short-interest ratio is currently 2.1 days. Currently, 1.1% of the company’s shares are sold short.
A number of hedge funds have recently made changes to their positions in MDWD. Delek Group Ltd. bought a new position in shares of Mediwound during the 1st quarter worth approximately $141,000. Meitav Dash Investments Ltd. grew its stake in shares of Mediwound by 0.6% during the 1st quarter. Meitav Dash Investments Ltd. now owns 598,508 shares of the biopharmaceutical company’s stock worth $2,993,000 after acquiring an additional 3,536 shares in the last quarter. Deutsche Bank AG grew its stake in shares of Mediwound by 73.5% during the 4th quarter. Deutsche Bank AG now owns 39,740 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 16,840 shares in the last quarter. Menta Capital LLC grew its stake in shares of Mediwound by 200.2% during the 1st quarter. Menta Capital LLC now owns 44,514 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 29,686 shares in the last quarter. Finally, Millennium Management LLC grew its stake in shares of Mediwound by 33.2% during the 4th quarter. Millennium Management LLC now owns 68,365 shares of the biopharmaceutical company’s stock worth $278,000 after acquiring an additional 17,048 shares in the last quarter. Hedge funds and other institutional investors own 30.78% of the company’s stock.
A number of brokerages recently weighed in on MDWD. ValuEngine downgraded shares of Virtu Financial from a “hold” rating to a “sell” rating in a research report on Tuesday, June 18th. Zacks Investment Research downgraded shares of Farmland Partners from a “hold” rating to a “sell” rating in a research report on Friday. Finally, Oppenheimer set a $22.00 target price on shares of Par Pacific and gave the stock a “buy” rating in a report on Monday, March 25th.
Mediwound (NASDAQ:MDWD) last announced its earnings results on Tuesday, May 21st. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.60 million. Mediwound had a negative return on equity of 383.19% and a negative net margin of 18.43%. On average, analysts predict that Mediwound will post -0.59 earnings per share for the current fiscal year.
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Featured Story: How to read a candlestick chart
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.